Digest Réseau Comment ça marche
Réseau
/
Sociétés
Id
Non vérifié

Idorsia Pharmaceuticals Ltd

Ce que nous écrivons

Annonces ÉconomiquesIndustrie pharmaceutique

81 communiqués de presse

Voir tous les communiqués de presse
10/08/2026
Industrie pharmaceutique
Annonces Économiques
Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V
Source
Idorsia Pharmaceuticals Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
29/07/2026
Industrie pharmaceutique
Annonces Économiques
QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth
Source
Idorsia Pharmaceuticals Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
26/07/2026
Industrie pharmaceutique
Annonces Économiques
Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant
Source
Idorsia Pharmaceuticals Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
23/07/2026
Industrie pharmaceutique
Annonces Économiques
Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call
Source
Idorsia Pharmaceuticals Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
30/06/2026
Industrie pharmaceutique
Annonces Économiques
Idorsia appoints Roland Wandeler as Chief Executive Officer
Source
Idorsia Pharmaceuticals Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
25/06/2026
Industrie pharmaceutique
Annonces Économiques
Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility
Source
Idorsia Pharmaceuticals Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
08/06/2026
Industrie pharmaceutique
Annonces Économiques
Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon
Source
Idorsia Pharmaceuticals Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
31/05/2026
Industrie pharmaceutique
Annonces Économiques
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology
Source
Idorsia Pharmaceuticals Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
31/05/2026
Industrie pharmaceutique
Annonces Économiques
New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
Source
Idorsia Pharmaceuticals Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
06/05/2026
Industrie pharmaceutique
Annonces Économiques
Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026
Source
Idorsia Pharmaceuticals Ltd
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0